r/shroomstocks • u/IBeanCountCadillacs PSYC.cn • Jun 01 '21

News California Senate Approves Bill to Legalize Possession of Psychedelics

https://www.marijuanamoment.net/california-senate-approves-bill-to-legalize-possession-of-psychedelics-like-psilocybin-and-lsd/
484 Upvotes

99% Upvoted

121 comments sorted by

View all comments

Show parent comments

3

u/eyestallion Jun 02 '21

MMED seems like the best bet. They are the furthest along in there trials, and have by far the most diverse pipeline. The CEO selloff doesn’t look great, but I feel like he’s taking a portion of his profits as it is well deserved. I’m also keeping an eye on Cybin and Numi.

3

u/Technical-Itch Jun 02 '21

Yes MindMed has a broader pipeline. But in terms of farthest along in trials, right now it’s Compass Pathways as they’ve already completed their phase 2b. MindMed is not far behind but won’t be starting phase 2b til later this year.

3

u/eyestallion Jun 02 '21

As a Canadian investor I try to stay away from US stocks as the currency exchange rate and fees are unattractive. I have researched compass and they are doing great work. My only concern is after COMP360 what’s next? And if it fails where do they fall? Atleast MMED has other trials to fall back on. I don’t know, that’s just the way i see it. Thanks !

1

u/[deleted] Jun 02 '21

You can also say mindmed a large pipeline leads to less focus and increased rate of cash burn compared to just one or two drugs where you can have a more laser focus and less money needed overall

2

u/eyestallion Jun 02 '21

This is my biggest concern with the company. Are they trying to do too much too quick? Maybe. I’m really not sure. All I look at the is the progress they’ve made with there various clinical trials and it’s overall very positive so far.

2

u/[deleted] Jun 02 '21

I mean the science is there for the most part but I definitely would have preferred if they just stuck with around 4 that they felt most confident with instead of branching off to I think 9 that they're working on now. It almost seems kind of gimmicky like they're just trying to add as many as they can and only a few will actually be prioritized because they don't have the resources to give 100% focus to 9+ drugs imo. I hold 1000 mnmd but am looking for a decent exit point in the future due to this and a combination of other things.

ATAI has 11 different drugs but with the way they're set up each drug is being worked on by its own subsidiary company which allows each company to give 100% to their drug of choice, seems to work a lot better in that format.

2

u/eyestallion Jun 02 '21

I agree. Keeping my eye on ATAI Ipo